Overview of immune cell redirecting bispecific antibodies investigated in ongoing clinical trials for hematologic malignancies
| Target . | Molecule/drug . | Condition . | Phase; status; NCT# . |
|---|---|---|---|
| BCMA + CD3 | JNJ-64007957 (Teclistamab) | MM | 1; recruiting; NCT03145181 1; recruiting; NCT04696809 2; recruiting; NCT04557098 |
| BMCA + CD3 | PF-06863135 (Elranatamab) | MM | 1; recruiting; NCT03269136 2; recruiting; NCT04649359 |
| BCMA + CD3 plus GPRC5D + CD3 | JNJ-64007957 (Teclistamab); JNJ-64407564 (Talquetamab) | MM | 1; recruiting; NCT04108195 1; recruiting; NCT04586426 |
| BCMA + CD3 | TNB-383B | MM | 1; recruiting; NCT03933735 |
| BCMA + CD3 | REGN5458 | MM | 1/2; recruiting; NCT03761108 |
| BCMA + CD3 | REGN5459 | MM | 1; recruiting; NCT04083534 |
| CD19 + CD3 | TNB-486 | B-cell lymphoma, FL | 1; recruiting; NCT04594642 |
| CD20 + CD3 | REGN1979 (Odronextamab) | NHL, HL, CLL | 1; active, not recruiting; NCT02651662, NCT02290951 2; active, not recruiting; NCT03888105 |
| CD20 + CD3 | RG7828 (Mosunetuzumab) | NHL, CLL | 1; recruiting; NCT02500407, NCT03671018, NCT03677141, NCT03677154 |
| CD33 + CD3 | AMG330 | AML | 1; recruiting; NCT02520427, NCT02106091 |
| CD33 + CD3 | AMV564 | AML, MDS | 1; active, not recruiting; NCT03516591, NCT03144245 |
| CD33 + CD3 | GEM333 | AML | 1; active, not recruiting; NCT03516760 |
| CD33 + CD3 | JNJ-67371244 | AML, MDS | 1; recruiting; NCT03915379 |
| CD33 + CD3 (with IL-15 crosslinker) | 161533 TriKE | MDS, AML, ASM | 1/2; recruiting; NCT03214666 |
| CD38 + CD3 | ISB 1342 | MM | 1/2; recruiting; NCT03309111 |
| CD123 + CD3 | MGD006 (Flotetuzumab) | AML, MDS | 1; recruiting; NCT02152956 1; recruiting; NCT04681105 |
| CD123 + CD3 | APVO436 | AML, MDS | 1; recruiting; NCT03647800 |
| CD123 + CD3 | JNJ-63709178 | AML | 1; recruiting; NCT02715011 |
| CD123 + CD3 | Xmab14045 (Vibecotamab) | AML, B-cell ALL, BPDCN, CML | 1; recruiting; NCT02730312 |
| GPRC5D + CD3 | JNJ-64407564 (Talquetamab) | Hematological malignancies | 1; recruiting; NCT03399799 1; recruiting; NCT04634552 |
| Target . | Molecule/drug . | Condition . | Phase; status; NCT# . |
|---|---|---|---|
| BCMA + CD3 | JNJ-64007957 (Teclistamab) | MM | 1; recruiting; NCT03145181 1; recruiting; NCT04696809 2; recruiting; NCT04557098 |
| BMCA + CD3 | PF-06863135 (Elranatamab) | MM | 1; recruiting; NCT03269136 2; recruiting; NCT04649359 |
| BCMA + CD3 plus GPRC5D + CD3 | JNJ-64007957 (Teclistamab); JNJ-64407564 (Talquetamab) | MM | 1; recruiting; NCT04108195 1; recruiting; NCT04586426 |
| BCMA + CD3 | TNB-383B | MM | 1; recruiting; NCT03933735 |
| BCMA + CD3 | REGN5458 | MM | 1/2; recruiting; NCT03761108 |
| BCMA + CD3 | REGN5459 | MM | 1; recruiting; NCT04083534 |
| CD19 + CD3 | TNB-486 | B-cell lymphoma, FL | 1; recruiting; NCT04594642 |
| CD20 + CD3 | REGN1979 (Odronextamab) | NHL, HL, CLL | 1; active, not recruiting; NCT02651662, NCT02290951 2; active, not recruiting; NCT03888105 |
| CD20 + CD3 | RG7828 (Mosunetuzumab) | NHL, CLL | 1; recruiting; NCT02500407, NCT03671018, NCT03677141, NCT03677154 |
| CD33 + CD3 | AMG330 | AML | 1; recruiting; NCT02520427, NCT02106091 |
| CD33 + CD3 | AMV564 | AML, MDS | 1; active, not recruiting; NCT03516591, NCT03144245 |
| CD33 + CD3 | GEM333 | AML | 1; active, not recruiting; NCT03516760 |
| CD33 + CD3 | JNJ-67371244 | AML, MDS | 1; recruiting; NCT03915379 |
| CD33 + CD3 (with IL-15 crosslinker) | 161533 TriKE | MDS, AML, ASM | 1/2; recruiting; NCT03214666 |
| CD38 + CD3 | ISB 1342 | MM | 1/2; recruiting; NCT03309111 |
| CD123 + CD3 | MGD006 (Flotetuzumab) | AML, MDS | 1; recruiting; NCT02152956 1; recruiting; NCT04681105 |
| CD123 + CD3 | APVO436 | AML, MDS | 1; recruiting; NCT03647800 |
| CD123 + CD3 | JNJ-63709178 | AML | 1; recruiting; NCT02715011 |
| CD123 + CD3 | Xmab14045 (Vibecotamab) | AML, B-cell ALL, BPDCN, CML | 1; recruiting; NCT02730312 |
| GPRC5D + CD3 | JNJ-64407564 (Talquetamab) | Hematological malignancies | 1; recruiting; NCT03399799 1; recruiting; NCT04634552 |
ASM, advanced systemic mastocytosis; BPDCN, blastic plasmacytoid dendritic cell neoplasm; CML, chronic myeloid leukemia; GPRC5D, G-protein–coupled receptor family C group 5 member D; TriKE, trispecific killer engager.